24/7 MN (AMEX: AIM) AIM IMMUNOTECH INC. shares have perked up more than 16% in pre-market trading on light volume and less than 1,000 trades as the company announces additional patients for its studies.
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.
24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.